Novo Nordisk sues Eli Lilly over allegedly misleading GLP-1 drug ads
NVO•Novo Nordisk alleges false advertising in Zepbound and Mounjaro campaigns
Novo Nordisk filed a federal lawsuit in New Jersey accusing Eli Lilly of false advertising in U.S. consumer campaigns for Zepbound and Mounjaro.
The complaint targets comparisons using Lilly’s highest doses against lower doses of Wegovy and Ozempic, omitting newer, more effective options.
Novo argues the ads exclude Wegovy 7.2 mg, cleared by the FDA in March 2026, which showed 18.8% average weight loss in a 72-week trial.
The suit seeks a permanent injunction to pull the comparative ads across platforms, backed by a corrective advertising campaign.
Novo signaled it may seek a preliminary injunction in the coming days to immediately block the advertising.
